Myeloproliferative neoplasms (MPN), comprising essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are hematological disorders of the myeloid lineage characterized by hyperproliferation of mature blood cells. The prediction of the clinical course and progression remains difficult and new therapeutic modalities are required. We conducted a CD34+ gene expression study to identify signatures and potential biomarkers in the different MPN subtypes with the aim to improve treatment and prevent the transformation from the rather benign chronic state to a more malignant aggressive state. We report here on a systematic gene expression analysis (GEA) of CD34+ peripheral blood or bone marrow cells derived from 30 patients with MPN including all subtypes (ET (n = 6), PV (n = 11), PMF (n = 9), secondary MF (SMF; post-ET-/post-PV-MF; n = 4)) and six healthy donors. GEA revealed a variety of differentially regulated genes in the different MPN subtypes vs. controls, with a higher number in PMF/SMF (200/272 genes) than in ET/PV (132/121). PROGENγ analysis revealed significant induction of TNFα/NF-κB signaling (particularly in SMF) and reduction of estrogen signaling (PMF and SMF). Consistently, inflammatory GO terms were enriched in PMF/SMF, whereas RNA splicing-associated biological processes were downregulated in PMF. Differentially regulated genes that might be utilized as diagnostic/prognostic markers were identified, such as AREG, CYBB, DNTT, TIMD4, VCAM1, and S100 family members (S100A4/8/9/10/12). Additionally, 98 genes (including CLEC1B, CMTM5, CXCL8, DACH1, and RADX) were deregulated solely in SMF and may be used to predict progression from early to late stage MPN.

Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Aachen Germany

Department of Hematology Oncology Hemostaseology and Stem Cell Transplantation Faculty of Medicine RWTH Aachen University Aachen Germany

Department of Internal Medicine Hematology and Oncology Masaryk University and University Hospital Brno Brno Czech Republic

Department of Orthopedic Surgery University Hospital RWTH Aachen Aachen Germany

Institute for Computational Genomics RWTH Aachen University Aachen Germany

Institute of Hematology and Blood Transfusion Prague Czech Republic

IZKF Genomics Core Facility RWTH Aachen University Medical School Aachen Germany

Joint Research Center for Computational Biomedicine RWTH Aachen Aachen Germany

Zobrazit více v PubMed

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant’Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schonegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R, Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390. doi: 10.1056/NEJMoa1311347. PubMed DOI

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–1790. doi: 10.1056/NEJMoa051113. PubMed DOI

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O’Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405. doi: 10.1056/NEJMoa1312542. PubMed DOI PMC

Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128–1138. doi: 10.1038/leu.2010.69. PubMed DOI PMC

Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667–679. doi: 10.1182/blood-2016-10-695940. PubMed DOI

Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310–318. doi: 10.1200/JCO.2017.76.4886. PubMed DOI

Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O’Neil L, O’Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416–1430. doi: 10.1056/NEJMoa1716614. PubMed DOI PMC

Hasselbalch HC. Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera? Haematologica. 2019;104(11):2119–2125. doi: 10.3324/haematol.2019.229039. PubMed DOI PMC

Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia. 2011;25(2):218–225. doi: 10.1038/leu.2010.269. PubMed DOI

Vannucchi AM, Harrison CN. Emerging treatments for classical myeloproliferative neoplasms. Blood. 2017;129(6):693–703. doi: 10.1182/blood-2016-10-695965. PubMed DOI

Patel AA. Odenike O (2020) Genomics of MPN progression. Hematology Am Soc Hematol Educ Program. 2020;1:440–449. doi: 10.1182/hematology.2020000129. PubMed DOI PMC

Berkofsky-Fessler W, Buzzai M, Kim MK, Fruchtman S, Najfeld V, Min DJ, Costa FF, Bischof JM, Soares MB, McConnell MJ, Zhang W, Levine R, Gilliland DG, Calogero R, Licht JD. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clin Cancer Res. 2010;16(17):4339–4352. doi: 10.1158/1078-0432.CCR-10-1092. PubMed DOI PMC

Catani L, Zini R, Sollazzo D, Ottaviani E, Vannucchi AM, Ferrari S, Baccarani M, Vianelli N, Lemoli RM, Manfredini R. Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. Leukemia. 2009;23(5):997–1000. doi: 10.1038/leu.2008.357. PubMed DOI

Guglielmelli P, Zini R, Bogani C, Salati S, Pancrazzi A, Bianchi E, Mannelli F, Ferrari S, Le Bousse-Kerdiles MC, Bosi A, Barosi G, Migliaccio AR, Manfredini R, Vannucchi AM. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms’ tumor gene 1 (WT1) Stem Cells. 2007;25(1):165–173. doi: 10.1634/stemcells.2006-0351. PubMed DOI

Čokić VP, Mossuz P, Han J, Socoro N, Beleslin-Čokić BB, Mitrović O, Subotički T, Diklić M, Leković D, Gotič M, Puri RK, Noguchi CT, Schechter AN. Microarray and proteomic analyses of myeloproliferative neoplasms with a highlight on the mTOR signaling pathway. PLoS ONE. 2015;10(8):1–23. doi: 10.1371/journal.pone.0135463. PubMed DOI PMC

Psaila B, Wang G, Rodriguez-Meira A, Li R, Heuston EF, Murphy L, Yee D, Hitchcock IS, Sousos N, O’Sullivan J, Anderson S, Senis YA, Weinberg OK, Calicchio ML, Center NIHIS, Iskander D, Royston D, Milojkovic D, Roberts I, Bodine DM, Thongjuea S, Mead AJ (2020) Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets. Mol Cell 78 (3):477–492 e478. doi:10.1016/j.molcel.2020.04.008 PubMed PMC

Nam AS, Kim KT, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand R, Omans ND, Alonso A, Sheridan C, Mariani M, Dai X, Harrington E, Pastore A, Cubillos-Ruiz JR, Tam W, Hoffman R, Rabadan R, Scandura JM, Abdel-Wahab O, Smibert P, Landau DA. Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature. 2019;571(7765):355–360. doi: 10.1038/s41586-019-1367-0. PubMed DOI PMC

Kirschner M, Maurer A, Wlodarski MW, Ventura Ferreira MS, Bouillon AS, Halfmeyer I, Blau W, Kreuter M, Rosewich M, Corbacioglu S, Beck J, Schwarz M, Bittenbring J, Radsak MP, Wilk CM, Koschmieder S, Begemann M, Kurth I, Schemionek M, Brummendorf TH, Beier F. Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita. Leukemia. 2018;32(8):1762–1767. doi: 10.1038/s41375-018-0125-x. PubMed DOI

Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, Maie T, Costa IG, Denecke B, Maurer A, Schubert C, Feldberg K, Gezer D, Brummendorf TH, Muller-Newen G, Mayer J, Racil Z, Kubesova B, Knudsen T, Sorensen AL, Holmstrom M, Kjaer L, Skov V, Larsen TS, Hasselbalch HC, Chatain N, Koschmieder S. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-alpha via JAK1/STAT1 activation. Leukemia. 2019;33(4):995–1010. doi: 10.1038/s41375-018-0295-6. PubMed DOI

Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118–127. doi: 10.1093/biostatistics/kxj037. PubMed DOI

Nangalia J, Green AR (2017) Myeloproliferative neoplasms: from origins to outcomes. Blood 130 (23):blood-2017–2006–782037. doi:10.1182/blood-2017-06-782037 PubMed

Schubert M, Klinger B, Klunemann M, Sieber A, Uhlitz F, Sauer S, Garnett MJ, Bluthgen N, Saez-Rodriguez J. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat Commun. 2018;9(1):20. doi: 10.1038/s41467-017-02391-6. PubMed DOI PMC

Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, Roberts J, Witkin M, Rapaport F, Teruya-Feldstein J, Qi J, Rampal R, Bernstein BE, Bradner JE, Levine RL (2018) Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell 33 (1):29–43 e27. doi:10.1016/j.ccell.2017.11.009 PubMed PMC

Hautin M, Mornet C, Chauveau A, Bernard D, Corcos L, Lippert E (2020) Splicing anomalies in myeloproliferative neoplasms: paving the way for new therapeutic venues. Cancers (Basel) 12 (8). doi:10.3390/cancers12082216 PubMed PMC

Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–426. doi: 10.1146/annurev-pharmtox-011112-140320. PubMed DOI PMC

Chatain N, Koschmieder S, Jost E (2020) Role of inflammatory factors during disease pathogenesis and stem cell transplantation in myeloproliferative neoplasms. Cancers (Basel) 12 (8). doi:10.3390/cancers12082250 PubMed PMC

Berasain C, Avila MA. Amphiregulin. Semin Cell Dev Biol. 2014;28:31–41. doi: 10.1016/j.semcdb.2014.01.005. PubMed DOI

Arpaia N, Green JA, Moltedo B, Arvey A, Hemmers S, Yuan S, Treuting PM, Rudensky AY. A distinct function of regulatory T cells in tissue protection. Cell. 2015;162(5):1078–1089. doi: 10.1016/j.cell.2015.08.021. PubMed DOI PMC

Haouas H, Haouas S, Uzan G, Hafsia A. Identification of new markers discriminating between myeloid and lymphoid acute leukemia. Hematology. 2010;15(4):193–203. doi: 10.1179/102453310X12647083620769. PubMed DOI

Huh YO, Smith TL, Collins P, Bueso-Ramos C, Albitar M, Kantarjian HM, Pierce SA, Freireich EJ. Terminal deoxynucleotidyl transferase expression in acute myelogenous leukemia and myelodysplasia as determined by flow cytometry. Leuk Lymphoma. 2000;37(3–4):319–331. doi: 10.3109/10428190009089432. PubMed DOI

Paiva AS, Paiva HDDO, Cavalcanti GB, Jr, Bahia F, Freitas RV, Silveira LS, Jr, Silva LK, Vasconcelos RC, Silva DG, Vl S, Gil EA, Januario G, Fernandes M, Jardim AS. Importance of detection of intracellular myeloperoxidase, CD13, CD79a, CD22, CD3 and terminal deoxynucleotidyl transferase by flow cytometry diagnosis of acute leukemias. Blood. 2018;132(Supplement 1):5194–5194. doi: 10.1182/blood-2018-99-118880. DOI

Goyette J, Geczy CL. Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids. 2011;41(4):821–842. doi: 10.1007/s00726-010-0528-0. PubMed DOI

Kovacic M, Mitrovic-Ajtic O, Beleslin-Cokic B, Djikic D, Suboticki T, Diklic M, Lekovic D, Gotic M, Mossuz P, Cokic VP. TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms. Cell Oncol (Dordr) 2018;41(5):541–553. doi: 10.1007/s13402-018-0392-6. PubMed DOI

Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, Nguyen M, Olsson A, Nawroth PP, Bierhaus A, Varki N, Kronenberg M, Freeze HH, Srikrishna G. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008;29(10):2035–2043. doi: 10.1093/carcin/bgn188. PubMed DOI PMC

Leimkuhler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, Banjanin B, Lam KH, Vogl T, Kuppe C, Stalmann USA, Busche G, Kreipe H, Gutgemann I, Krebs P, Banz Y, Boor P, Tai EW, Brummendorf TH, Koschmieder S, Crysandt M, Bindels E, Kramann R, Costa IG, Schneider RK. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2020 doi: 10.1016/j.stem.2020.11.004. PubMed DOI PMC

Gleitz HFE, Dugourd AJF, Leimkuhler NB, Snoeren IAM, Fuchs SNR, Menzel S, Ziegler S, Kroger N, Triviai I, Busche G, Kreipe H, Banjanin B, Pritchard JE, Hoogenboezem R, Bindels EM, Schumacher N, Rose-John S, Elf S, Saez-Rodriguez J, Kramann R, Schneider RK. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood. 2020;136(18):2051–2064. doi: 10.1182/blood.2019004095. PubMed DOI PMC

Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356–1363. doi: 10.1200/JCO.2010.32.9490. PubMed DOI

Colonna M, Samaridis J, Angman L. Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells. Eur J Immunol. 2000;30(2):697–704. doi: 10.1002/1521-4141(200002)30:2<697::AID-IMMU697>3.0.CO;2-M. PubMed DOI

Moriyama M, Sato T, Inoue H, Fukuyama S, Teranishi H, Kangawa K, Kano T, Yoshimura A, Kojima M. The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. J Exp Med. 2005;202(2):217–224. doi: 10.1084/jem.20050248. PubMed DOI PMC

Schemionek M, Herrmann O, Reher MM, Chatain N, Schubert C, Costa IG, Hanzelmann S, Gusmao EG, Kintsler S, Braunschweig T, Hamilton A, Helgason GV, Copland M, Schwab A, Muller-Tidow C, Li S, Holyoake TL, Brummendorf TH, Koschmieder S. Mtss1 is a critical epigenetically regulated tumor suppressor in CML. Leukemia. 2016;30(4):823–832. doi: 10.1038/leu.2015.329. PubMed DOI

Schemionek M, Kharabi Masouleh B, Klaile Y, Krug U, Hebestreit K, Schubert C, Dugas M, Buchner T, Wormann B, Hiddemann W, Berdel WE, Brummendorf TH, Muller-Tidow C, Koschmieder S. Identification of the adapter molecule MTSS1 as a potential oncogene-specific tumor suppressor in acute myeloid leukemia. PLoS ONE. 2015;10(5):e0125783. doi: 10.1371/journal.pone.0125783. PubMed DOI PMC

Shao L, Cui Y, Li H, Liu Y, Zhao H, Wang Y, Zhang Y, Ng KM, Han W, Ma D, Tao Q. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res. 2007;13(19):5756–5762. doi: 10.1158/1078-0432.CCR-06-3082. PubMed DOI

Wang D, Xu MR, Wang T, Li T, Zhu J. MTSS1 overexpression correlates with poor prognosis in colorectal cancer. J Gastrointest Surg. 2011;15(7):1205–1212. doi: 10.1007/s11605-011-1546-2. PubMed DOI

Mertz KD, Pathria G, Wagner C, Saarikangas J, Sboner A, Romanov J, Gschaider M, Lenz F, Neumann F, Schreiner W, Nemethova M, Glassmann A, Lappalainen P, Stingl G, Small JV, Fink D, Chin L, Wagner SN. MTSS1 is a metastasis driver in a subset of human melanomas. Nat Commun. 2014;5:3465. doi: 10.1038/ncomms4465. PubMed DOI

Dungrawala H, Bhat KP, Le Meur R, Chazin WJ, Ding X, Sharan SK, Wessel SR, Sathe AA, Zhao R, Cortez D (2017) RADX promotes genome stability and modulates chemosensitivity by regulating RAD51 at replication forks. Mol Cell 67 (3):374–386 e375. doi:10.1016/j.molcel.2017.06.023 PubMed PMC

Liu Y, Zhou R, Yuan X, Han N, Zhou S, Xu H, Guo M, Yu S, Zhang C, Yin T, Wu K. DACH1 is a novel predictive and prognostic biomarker in hepatocellular carcinoma as a negative regulator of Wnt/beta-catenin signaling. Oncotarget. 2015;6(11):8621–8634. doi: 10.18632/oncotarget.3281. PubMed DOI PMC

Chen S, Li J, Zhou P, Zhi X. SPTBN1 and cancer, which links? J Cell Physiol. 2020;235(1):17–25. doi: 10.1002/jcp.28975. PubMed DOI

Barosi G, Rosti V, Catarsi P, Villani L, Abba C, Carolei A, Magrini U, Gale RP, Massa M, Campanelli R. Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia. 2020 doi: 10.1038/s41375-020-0926-6. PubMed DOI

Verstovsek S, Komrokji RS. A comprehensive review of pacritinib in myelofibrosis. Future Oncol. 2015;11(20):2819–2830. doi: 10.2217/fon.15.200. PubMed DOI PMC

Hasselbalch HC, Bjorn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015;2015:102476. doi: 10.1155/2015/102476. PubMed DOI PMC

Fisher DAC, Malkova O, Engle EK, Miner CA, Fulbright MC, Behbehani GK, Collins TB, Bandyopadhyay S, Zhou A, Nolan GP, Oh ST. Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia. 2017;31(9):1962–1974. doi: 10.1038/leu.2016.377. PubMed DOI PMC

Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, Roberts J, Witkin M, Rapaport F, Teruya-Feldstein J, Qi J, Rampal R, Bernstein BE, Bradner JE, Levine RL. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33(4):785–787. doi: 10.1016/j.ccell.2018.03.024. PubMed DOI PMC

Sanchez-Aguilera A, Arranz L, Martin-Perez D, Garcia-Garcia A, Stavropoulou V, Kubovcakova L, Isern J, Martin-Salamanca S, Langa X, Skoda RC, Schwaller J, Mendez-Ferrer S. Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis. Cell Stem Cell. 2014;15(6):791–804. doi: 10.1016/j.stem.2014.11.002. PubMed DOI

Harrison C, Baxter J, Boucher RH, McKerrell T, Jackson A, Fletcher RS, Mead AJ, Knapper S, Ewing J, Butt NM, Jain M, Francis S, Clark FJ, Coppell J, McMullin MF, Wadelin F, Narayanan S, Milojkovic D, Drummond MW, Sekhar M, Paramor M, Roberts J, Glover R, Harris E, Grassi L, Rodriguez-Meira A, Carroll J, Martín J-E, Corbizi Fattori G, Fang Z, Godfrey AL, Méndez-Ferrer S. Effects of tamoxifen on the mutant allele burden and disease course in patients with myeloproliferative neoplasms - results of the Tamarin Study. Blood. 2020;136(Supplement 1):33–35. doi: 10.1182/blood-2020-134764. DOI

Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL, Hehlmann R, Maria Vannucchi A, Cervantes F, Silver RT, Barbui T. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016;30(5):1018–1024. doi: 10.1038/leu.2016.12. PubMed DOI

Koschmieder S, Chatain N. Role of inflammation in the biology of myeloproliferative neoplasms. Blood Rev. 2020;42:100711. doi: 10.1016/j.blre.2020.100711. PubMed DOI

Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017;130(26):2848–2859. doi: 10.1182/blood-2017-05-784942. PubMed DOI PMC

Marty C, Lacout C, Droin N, Le Couédic JP, Ribrag V, Solary E, Vainchenker W, Villeval JL, Plo I. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia. 2013;27(11):2187–2195. doi: 10.1038/leu.2013.102. PubMed DOI

Nageswara Rao T, Hansen N, Hilfiker J, Rai S, Majewska JM, Lekovic D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan TW, Lane AN, Handschin C, Dirnhofer S, Kroger N, Hess C, Radimerski T, Koschmieder S, Cokic VP, Skoda RC. JAK2 mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019 doi: 10.1182/blood.2019000162. PubMed DOI PMC

Baumeister J, Chatain N, Hubrich A, Maie T, Costa IG, Denecke B, Han L, Kustermann C, Sontag S, Sere K, Strathmann K, Zenke M, Schuppert A, Brummendorf TH, Kranc KR, Koschmieder S, Gezer D. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms. Leukemia. 2019 doi: 10.1038/s41375-019-0629-z. PubMed DOI

Hasselbalch HC, Thomassen M, Riley CH, Kjaer L, Larsen TS, Jensen MK, Bjerrum OW, Kruse TA, Skov V (2014) Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression. PLoS One 9 (11):e112786. doi:10.1371/journal.pone.0112786 PubMed PMC

Tsai JJ, Dudakov JA, Takahashi K, Shieh JH, Velardi E, Holland AM, Singer NV, West ML, Smith OM, Young LF, Shono Y, Ghosh A, Hanash AM, Tran HT, Moore MA, van den Brink MR. Nrf2 regulates haematopoietic stem cell function. Nat Cell Biol. 2013;15(3):309–316. doi: 10.1038/ncb2699. PubMed DOI PMC

Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86(3):557–566. doi: 10.1189/jlb.1008647. PubMed DOI

Abdulkarim K, Girodon F, Johansson P, Maynadie M, Kutti J, Carli PM, Bovet E, Andreasson B. AML transformation in 56 patients with Ph- MPD in two well defined populations. Eur J Haematol. 2009;82(2):106–111. doi: 10.1111/j.1600-0609.2008.01163.x. PubMed DOI

Braig M, Pallmann N, Preukschas M, Steinemann D, Hofmann W, Gompf A, Streichert T, Braunschweig T, Copland M, Rudolph KL, Bokemeyer C, Koschmieder S, Schuppert A, Balabanov S, Brummendorf TH. A ‘telomere-associated secretory phenotype’ cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. Leukemia. 2014;28(10):2028–2039. doi: 10.1038/leu.2014.95. PubMed DOI

Chan SL, Baumbach GL. Deficiency of Nox2 prevents angiotensin II-induced inward remodeling in cerebral arterioles. Front Physiol. 2013;4:133. doi: 10.3389/fphys.2013.00133. PubMed DOI PMC

Hsu SY, Kaipia A, Zhu L, Hsueh AJ. Interference of BAD (Bcl-xL/Bcl-2-associated death promoter)-induced apoptosis in mammalian cells by 14–3-3 isoforms and P11. Mol Endocrinol. 1997;11(12):1858–1867. doi: 10.1210/mend.11.12.0023. PubMed DOI

Brenner AK, Bruserud O. S100 proteins in acute myeloid leukemia. Neoplasia. 2018;20(12):1175–1186. doi: 10.1016/j.neo.2018.09.007. PubMed DOI PMC

Rouleau P, Vandal K, Ryckman C, Poubelle PE, Boivin A, Talbot M, Tessier PA. The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis. Clin Immunol. 2003;107(1):46–54. doi: 10.1016/s1521-6616(02)00043-8. PubMed DOI

Cheng L, Ruan Z. Tim-3 and Tim-4 as the potential targets for antitumor therapy. Hum Vaccin Immunother. 2015;11(10):2458–2462. doi: 10.1080/21645515.2015.1056953. PubMed DOI PMC

Tan X, Zhang Z, Yao H, Shen L. Tim-4 promotes the growth of colorectal cancer by activating angiogenesis and recruiting tumor-associated macrophages via the PI3K/AKT/mTOR signaling pathway. Cancer Lett. 2018;436:119–128. doi: 10.1016/j.canlet.2018.08.012. PubMed DOI

Ozono Y, Shide K, Kameda T, Kamiunten A, Tahira Y, Sekine M, Akizuki K, Nakamura K, Iwakiri H, Sueta M, Hidaka T, Kubuki Y, Yamamoto S, Hasuike S, Sawaguchi A, Nagata K, Shimoda K. Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice. Leukemia. 2021;35(2):454–467. doi: 10.1038/s41375-020-0880-3. PubMed DOI PMC

Edelmann B, Gupta N, Schnoeder TM, Oelschlegel AM, Shahzad K, Goldschmidt J, Philipsen L, Weinert S, Ghosh A, Saalfeld FC, Nimmagadda SC, Muller P, Braun-Dullaeus R, Mohr J, Wolleschak D, Kliche S, Amthauer H, Heidel FH, Schraven B, Isermann B, Muller AJ, Fischer T. JAK2-V617F promotes venous thrombosis through beta1/beta2 integrin activation. J Clin Invest. 2018;128(10):4359–4371. doi: 10.1172/JCI90312. PubMed DOI PMC